Celldex Therapeutics (CLDX) Posts Narrower than Expected Q2 Loss of 27c/Sh.
Tweet
Share
E-mailGet Alerts CLDX Hot Sheet
Join SI Premium – FREE
Celldex Therapeutics (NASDAQ: CLDX) reported Q2 EPS of ($0.27), $0.02 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $1.95 million versus the consensus estimate of $2.43 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guggenheim flags this biotech stocks as one of its top picks
- Smith & Wesson Brands (SWBI) Tops Q4 EPS by 15c
- Safe Bulkers (SB) Tops Q1 EPS by 7c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
